<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24210" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Adult T-Cell Leukemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Durer</surname>
            <given-names>Ceren</given-names>
          </name>
          <aff>SUNY Upstate Medical University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Babiker</surname>
            <given-names>Hani M.</given-names>
          </name>
          <aff>University of Arizona Cancer Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ceren Durer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hani Babiker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24210.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Adult T- cell leukemia (ATL) is a rare and aggressive peripheral T-cell neoplasm associated with human T-cell leukemia virus type -1 (HTLV-1) infection. It is classified into four different clinical variants that are acute, lymphomatous, chronic, and smoldering. ATL is associated with poor prognosis with short overall survival despite treatment. This activity reviews the evaluation and treatment of ATL and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etiology of adult T cell leukemia.</p></list-item><list-item><p>Describe the evaluation of adult T cell leukemia.</p></list-item><list-item><p>Outline the management of adult T cell leukemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24210&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24210">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24210.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Adult T-cell leukemia (ATL) is a highly aggressive mature T-cell neoplasm associated with human T-cell lymphotropic virus type 1 (HTLV-1) infection, which affects around 10 million people in the world. Of them, approximately 1-5% eventually develop symptomatic ATL.<xref ref-type="bibr" rid="article-24210.r1">[1]</xref> HTLV-1 is the first human retrovirus and is endemic in the north and south parts of Japan, the Caribbean region, Africa, some parts in the Middle East, South, and Central America.<xref ref-type="bibr" rid="article-24210.r2">[2]</xref> HTLV-1 transmission occurs from mother to child through breastfeeding, sexual interaction, and blood transfusion. Initial presentation may vary, including generalized lymph node swelling, hepatosplenomegaly, skin involvement, and opportunistic infections.</p>
        <p>ATL is classified into four clinical subtypes: acute, lymphoma, chronic, and smoldering type. Aggressive ATL (acute, lymphoma, and chronic type with unfavorable prognostic factors) have a poor prognosis with an overall survival rate of less than a year. The favorable chronic and smoldering subtypes carry a relatively good prognosis, and watchful waiting is generally preferred until disease progression occurs. Patients who&#x000a0;have rapidly progressive disease carry a poor prognosis due to the chemo-resistance of malignant cells and severe immunosuppression.<xref ref-type="bibr" rid="article-24210.r3">[3]</xref></p>
      </sec>
      <sec id="article-24210.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Adult T cell leukemia is primarily caused by HTLV-1 infection that usually remains asymptomatic. Transactivator protein (tax) and HTLV-1 basic leucine zipper factor (HBZ), the two viral oncoproteins, play an essential role in the development of disease and progression. Tax protein expression takes part in the onset of neoplastic transformation. HBZ protein is expressed on all infected malignant cell lines, which&#x000a0;is responsible for the proliferation of leukemic cells.<xref ref-type="bibr" rid="article-24210.r4">[4]</xref></p>
      </sec>
      <sec id="article-24210.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Prevalence is high in southwestern Japan, the Caribbean region, West Africa, and northeast Iran, south and Central America, and there is a slight male predominance across the studies. HTLV-1 and ATL are rarely reported in North America. A recent report of ATL cases from 2001 to 2015 in North America showed an incidence rate of 0.06 per 100.000 population.<xref ref-type="bibr" rid="article-24210.r5">[5]</xref> In Japan, the annual incidence was reported to be around 60 per 100.000 carriers with 1000 death each year.<xref ref-type="bibr" rid="article-24210.r6">[6]</xref></p>
      </sec>
      <sec id="article-24210.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>ATL is uniformly associated with HTLV-I infection of CD4-positive T cells that play a significant role in the pathogenesis of ATL.<xref ref-type="bibr" rid="article-24210.r7">[7]</xref> The tumor-initiating cell appears to be an HTLV-I infected CD4-positive memory T cell with stem cell-like properties. However, HTLV-1 infection is not enough for malignant transformation. HTLV-1 infects CD4 T-cells and causes cell proliferation and transformation through viral gene products that interact with host proteins and alter gene function. HTLV-1 genome contains Gag, Pol, Env, and regulatory genes Tax and HBZ. Inducing the death of infected cells is achieved by Tax-specific cytotoxic T-cell responses and antibody response against viral proteins (Env, Gag).<xref ref-type="bibr" rid="article-24210.r8">[8]</xref></p>
        <p>Tax and HTLV-1 B-zip protein (HBZ) are the viral regulatory proteins associated with neoplastic transformation and proliferation. HTLV-1 can escape from the host immune response by reducing Tax and activating HBZ expression. HBZ inhibits Tax-dependent viral transcription and induces its own expression. Therefore, it maintains chronic infection. HBZ viral protein is the only one continuously expressed in ATL. It has been reported that clones of ATL cells with the same proviral integration site can have different T cell receptor rearrangements, raising the possibility that ATL may arise from immature HTLV-1 infected hematopoietic progenitors.<xref ref-type="bibr" rid="article-24210.r9">[9]</xref></p>
        <p>ATL is frequently associated with hypercalcemia, which can be severe. The hypercalcemia seen in ATL is thought to arise from cytokines released from the malignant cells. There are several proposed mechanisms, including the production of parathyroid hormone-related protein (PTH-RP), tumor necrosis factor-beta, or interleukin-1, increased RANKL expression (receptor activator of nuclear factor-kB ligand). These factors may also contribute to the genesis of the lytic bone lesions, increased bone turnover, increased serum alkaline phosphatase.<xref ref-type="bibr" rid="article-24210.r10">[10]</xref></p>
      </sec>
      <sec id="article-24210.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Adult T cell leukemia is clinically classified into four subgroups defined by the Shimoyama criteria: acute, chronic, lymphoma, and smoldering<xref ref-type="bibr" rid="article-24210.r11">[11]</xref>.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acute</bold> subtype accounts for &#x0003e;50% of cases and presents with leukemic pictures, systemic symptoms, lymphadenopathy, organ infiltration, hypercalcemia, and high serum lactate dehydrogenase (LDH) level.</p>
          </list-item>
          <list-item>
            <p><bold>Chronic</bold> ATL is characterized by the presence of skin, lung and liver involvement, lymphocytosis (&#x02265;4 &#x000d7; 103 cells/&#x003bc;L) with normal LDH, and calcium.&#x000a0;The chronic&#x000a0;ATL has two subgroups: favorable and unfavorable. The unfavorable subgroup&#x000a0;presents with at least one poor prognostic factor&#x000a0;such as&#x000a0;elevated LDH, elevated BUN, and decreased albumin<xref ref-type="bibr" rid="article-24210.r12">[12]</xref>.</p>
          </list-item>
          <list-item>
            <p>The <bold>lymphomatous</bold> form is characterized by extensive lymphadenopathy, organomegaly, markedly increased LDH, hypercalcemia, and less than 1% presence of circulating leukemic cells in the peripheral blood.</p>
          </list-item>
          <list-item>
            <p>The <bold>smoldering</bold> form presents with lung or skin involvement, normal lymphocyte count, normal or mildly increased LDH.</p>
          </list-item>
        </list>
        <p>All&#x000a0;forms of ATL may demonstrate variable skin findings. Tumor lysis&#x000a0;syndrome, as well as central nervous system involvement, may be seen in aggressive ATL. Due to severe immunosuppression, all ATL patients are at increased risk for infections, including fungal, viral, and parasitic infections, specifically strongyloidiasis.</p>
      </sec>
      <sec id="article-24210.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosis of&#x000a0;adult T cell leukemia requires a comprehensive history review in conjunction with laboratory and pathologic survey. ATL is diagnosed mainly in patients from HTLV-1-endemic areas, e.g., Southwestern Japan, the Caribbean area, and South America, sub-Saharan Africa, and some regions of the Middle East and Australo-Melanesia.<xref ref-type="bibr" rid="article-24210.r13">[13]</xref> HTLV-1 is transmitted by sexual intercourse, prolonged breast-feeding (at least six months), and exposure to contaminated blood products that contain HTLV-1 infected lymphocytes.&#x000a0;Hypercalcemia is noted in approximately 70% of ATL patients. It is multifactorial in etiology, with the most prominent mechanism being humoral hypercalcemia of malignancy.<xref ref-type="bibr" rid="article-24210.r14">[14]</xref>&#x000a0;PTHrP is overexpressed in ATL cells, and it is associated with lytic bone lesions. However, PTHrP mRNA is highly expressed in aggressive type ATL when compared to indolent subtypes. Refractory hypercalcemia is also rarely seen in HTLV-1 induced ATL, and it can cause renal dysfunction, neuropsychiatric disturbances, and paralytic ileus on presentation.<xref ref-type="bibr" rid="article-24210.r15">[15]</xref><xref ref-type="bibr" rid="article-24210.r16">[16]</xref>&#x000a0;Severe eosinophilia may be present. Dysregulation of the Th2 response against opportunistic pathogens has been blamed for causing eosinophilia.<xref ref-type="bibr" rid="article-24210.r17">[17]</xref> In patients with disseminated strongyloidiasis may also present with eosinopenia.</p>
        <p>In the acute and chronic leukemic phase, the white blood cell count may increase with circulating atypical cells. The peripheral blood smear may show condensed chromatin with a convoluted or polylobated nucleus, often called a &#x0201c;flower cell&#x0201d; or &#x0201c;cloverleaf&#x0201d; that is pathognomonic for ATL.<xref ref-type="bibr" rid="article-24210.r18">[18]</xref>&#x000a0;HTLV-1 infection should be confirmed by ELISA and Western Blot and/or PCR (if Western Blot is indeterminate). The sensitivity for the diagnosis of HTLV-1 is higher with ELISA than with Western Blot and negative test rules out ATL.<xref ref-type="bibr" rid="article-24210.r19">[19]</xref></p>
        <p>Many other cytologic variants can be observed, such as large cells, anaplastic cells, and S&#x000e9;zary-like cells. Overall, the recommended panel should include CD3, CD4, CD5, CD7, CD8, CD25, and CD30 for the diagnosis.<xref ref-type="bibr" rid="article-24210.r20">[20]</xref> The expression&#x000a0;of CD30 is more common in the lymphoma subtype rather than the acute subtype.&#x000a0;There are no specific chromosomal abnormalities associated with ATL. Multiple nonspecific chromosomal abnormalities were reported in the literature, including trisomy 3, trisomy 7, monosomy X, and defects in chromosomes 6 and 14.<xref ref-type="bibr" rid="article-24210.r21">[21]</xref> These abnormalities occur more commonly in the aggressive types compared with the chronic type.</p>
        <p>An excisional lymph node biopsy, skin biopsy, and GI tract biopsy&#x000a0;in conjunction with flow cytometry and immunohistochemistry (IHC) are helpful for the diagnosis.&#x000a0;Bone marrow aspiration and biopsy may also be&#x000a0;needed for diagnosis and staging.&#x000a0;Anaplastic lymphoma kinase (ALK), paired box 5 (PAX5), and terminal deoxynucleotidyl transferase (TdT) are negative in the lymphoma subtype of ATL. A high level of Ki-67 proliferation index is associated with aggressive ATL.<xref ref-type="bibr" rid="article-24210.r20">[20]</xref>&#x000a0;</p>
        <p>In a clinical setting, evaluation should always include a complete cell blood count with differential, peripheral blood smear, LDH, a TLS panel, including uric acid, phosphate, calcium, potassium, and creatinine levels, and a serum concentration of soluble interleukin 2 (IL-2) receptor. The screening for Glucose-6-phosphate dehydrogenase (G6PD) deficiency should also be considered before proceeding to TLS treatment with rasburicase. HIV and hepatitis panel should also be sent. All patients with newly diagnosed aggressive ATL should have a human leukocyte antigen (HLA) typing as a part of the initial workup.<xref ref-type="bibr" rid="article-24210.r12">[12]</xref></p>
        <p>All patients with aggressive ATL should receive imaging tests to evaluate the extent of lymphadenopathy, splenomegaly, organ infiltration, and skeletal involvement. Either computed tomography (CT) with contrast or positron-emission tomography-computed tomography (PET-CT) should be included as part of the workup; however, treatment should not be delayed solely to obtain PET-CT.&#x000a0;CT scan or MRI of the brain and lumbar puncture should also be considered to evaluate the central nervous system involvement by ATL cells or opportunistic infection, especially for aggressive ATL.</p>
      </sec>
      <sec id="article-24210.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Patients with acute, lymphomatous, or unfavorable chronic type adult T cell leukemia carry a poor prognosis and have a median overall survival (OS) measured in months.&#x000a0;Treatment is tailored according to clinical subtype and patients characteristics. Chemotherapy or antiviral regimen is generally the first-line treatment for aggressive type (acute, lymphoma, and chronic with unfavorable features). Antiviral regimen or watchful waiting is a reasonable first-line for smoldering and favorable chronic subtypes. For skin lesions, ultraviolet B (NB-UVB) and psoralen and ultraviolet A (PUVA) can be used.</p>
        <p>
<bold>1. Antiviral therapy</bold>
</p>
        <p>Patients with leukemic forms of ATL showed improved results with first-line antiviral therapy (zidovudine and interferon), whereas patients with lymphoma type showed a better outcome with chemotherapy. The clinical use of AZT-IFN was first reported by Gill et al. in 1995 for 19 patients with acute-lymphomatous forms of ATL.<xref ref-type="bibr" rid="article-24210.r22">[22]</xref> Most of the patients were in the acute form of the disease, and seven patients had either relapse or treatment failure. This study reported a good overall response rate (ORR) of 58% with complete remission (CR) rate of 26%. The median OS was relatively poor (4.8 months) in previously untreated ATL patients as compared to the survival in the chemotherapy trials by Japan Clinical Oncology Group (JCOG), and several factors were thought to be attributable to this result including disease characteristics. A prospective phase II study by Hermine et al. demonstrated the objective response rate (ORR) of 92% and CR of 58% for the 13 patients treated with AZT-IFN combination as first-line therapy.<xref ref-type="bibr" rid="article-24210.r23">[23]</xref> The median OS was reported at 11 months. However, most of the patients eventually relapsed despite encouraging response rates. A meta-analysis of 254 ATL patients (116 acute, 18 chronic, 11 smoldering, 100 lymphoma patients) reported a five-year OS rate of 46% versus 20% in patients who received first-line antiviral therapy versus first-line chemotherapy, respectively. In the same study, patients with acute ATL who achieved CR with AZT-IFN demonstrated 82% of OS at five years, and those with chronic and smoldering showed 100% of OS at five years.<xref ref-type="bibr" rid="article-24210.r24">[24]</xref> A randomized phase III clinical trial was conducted by the JCOG-LSG to evaluate the efficacy of the combination of AZT and IFN versus watchful waiting for indolent-type ATL patients. Arsenic trioxide, in combination with IFN and AZT, was evaluated in 10 newly diagnosed chronic ATL patients, and ORR was 100%.<xref ref-type="bibr" rid="article-24210.r25">[25]</xref></p>
        <p>
<bold>2. Chemotherapy</bold>
</p>
        <p>Different chemotherapy regimens have been studied for ATL patients. Most frequently used chemotherapies are VCAP-AMP-VECP (vincristine, cyclophosphamide, doxorubicin, prednisone-doxorubicin, ranimustine, and prednisone-vindesine, etoposide, carboplatin, prednisone), modified EPOCH (etoposide, prednisolone, vincristine, carboplatin, and doxorubicin; carboplatin is substituted for cyclophosphamide), hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone).</p>
        <p>The Japanese Clinical Oncology Group (JCOG) has initiated a number of clinical trials to evaluate different chemotherapies in Japan. A phase III study from JCOG compared the VCAP-AMP-VECP regimen (known as LSG-15) to biweekly CHOP in untreated acute, lymphoma, or unfavorable chronic ATL patients. The 3-year OS was 24% versus 13% in the VCAP-AMP-VECP arm and CHOP arm, respectively. CR rate (40% versus 25%) and the median OS (13 months versus 11 months) were also superior in VCAP-AMP-VECP arm as compared to CHOP arm. In this study, patients were also administered G-CSF and CNS prophylaxis with cytarabine and intrathecal methotrexate and prednisone.<xref ref-type="bibr" rid="article-24210.r26">[26]</xref> Based on the results, The VCAP-AMP-VECP combination is currently a standard chemotherapeutic regimen for aggressive ATL in Japan.&#x000a0;Other recommended alternative regimens in the US include dose-adjusted EPOCH, CHOP, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD).<xref ref-type="bibr" rid="article-24210.r27">[27]</xref><xref ref-type="bibr" rid="article-24210.r28">[28]</xref>&#x000a0;For the elderly patients who are not able to tolerate aggressive chemotherapy, CHOP or CHOP-like regimens can be suggested.</p>
        <p>
<bold>3.&#x000a0;Allogeneic Stem Cell Transplantation</bold>
</p>
        <p>The role of stem cell transplantation (SCT) has been investigated in aggressive ATL, given the poor outcomes with standard treatment modalities. Few studies have been reported autologous SCT, and it has been shown to be associated with poor clinical outcomes, including high transplantation-related mortality.<xref ref-type="bibr" rid="article-24210.r29">[29]</xref>&#x000a0;In 1996, the first successful allogeneic bone marrow transplantation was reported.<xref ref-type="bibr" rid="article-24210.r30">[30]</xref> PCR on peripheral blood became negative for HTLV-I after transplantation, and the patient remained in complete remission in 23 months. Allo-SCT was suggested as a new strategy to eradicate HTLV1-positive cells. However, treatment-related toxicity and mortality were reported by 40% for immunocompromised patients. In a large nationwide Japanese retrospective study of 386 patients who underwent allogeneic SCT, overall survival at three years was 33% in a median follow-up of 41 months. Donor HTLV-1 seropositivity was found to be adversely associated with disease-related mortality in patients who received related grafts.<xref ref-type="bibr" rid="article-24210.r31">[31]</xref></p>
        <p>Retrospective studies showed no significant difference in overall survival between myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC), although a mild trend for overall survival was observed in favor of RIC-received older patients.<xref ref-type="bibr" rid="article-24210.r32">[32]</xref>&#x000a0;In a recent meta-analysis, the pooled rates of CR, OS, and PFS were reported at 73%, 40%, and 37%, respectively. The incidence of relapse and non-relapse mortality (NRM) was found to be high at 36% and 29%, respectively.<xref ref-type="bibr" rid="article-24210.r33">[33]</xref>&#x000a0;In an updated retrospective study of 1594 patients with acute and lymphoma ATL, significantly prolonged median survival time was observed in patients who received the transplant in the first remission when compared to those transplanted in the setting of primary refractory or relapsed disease (22 months vs. 3 months).<xref ref-type="bibr" rid="article-24210.r34">[34]</xref></p>
        <p>
<bold>4.&#x000a0;Monoclonal Antibody Therapy</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>
<bold> Brentuximab Vedotin</bold>
</p>
          </list-item>
        </list>
        <p>Brentuximab vedotin (BV) is a CD30-directed monoclonal antibody. The efficacy and safety were studied in clinical trials for ATL patients. A phase I study evaluated the combination of frontline BV and cyclophosphamide, doxorubicin, and prednisone (CHP) in CD30 positive peripheral T-cell lymphoma with all patients, including ATL, achieving CR.<xref ref-type="bibr" rid="article-24210.r35">[35]</xref> After a median follow up of 59.6 months, 50% of the patients showed durable responses and median PFS and OS were not reached.<xref ref-type="bibr" rid="article-24210.r36">[36]</xref>&#x000a0;The ECHELON-2 trial compared BV-CHP combination with CHOP in 452 newly diagnosed CD30-positive peripheral T-cell lymphoma patients. BV-CHP combination showed significantly better progression-free survival and overall survival as compared to CHOP. However, the number of ATL patients was quite limited in this study.<xref ref-type="bibr" rid="article-24210.r37">[37]</xref> A phase II study is currently active to assess the efficacy and safety of BV and combination chemotherapy.</p>
        <p><bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0;</bold>2.<bold> Mogamulizumab</bold></p>
        <p>Mogamulizumab is a humanized anti-CCR4 monoclonal antibody that is approved for relapsed or resistant ATL in Japan. The single-agent activity was demonstrated in a phase II study with the ORR of 50%, OS of 14 months, and progression-free survival of 5.3 months, months in relapsed ATL patients.<xref ref-type="bibr" rid="article-24210.r38">[38]</xref> A phase II randomized study compared Mogamulizumab plus LSG-15 regimen with LSG-15 alone for untreated aggressive ATL. &#x000a0;A CR rate and median PFS were 52% versus 33% and 8.5 months versus 6.3 months for the mogamulizumab plus LSG-15 arm versus the single LSG-15 arm, respectively.<xref ref-type="bibr" rid="article-24210.r39">[39]</xref> Studies reported frequent immune-related side effects, including skin rash, infusion reactions.</p>
        <p>A phase II trial that was done outside Japan comparing Mogamulizumab with chemotherapy in 71 relapsed/refractory ATL patients showed the single-agent activity with ORR of 11% versus 0%. Several retrospective studies also reported severe acute graft-versus-host disease (GvHD) with the use of Mogamulizumab, especially prior to allo-HSCT.<xref ref-type="bibr" rid="article-24210.r40">[40]</xref> A study showed significant survival outcomes with increased nonrelapse mortality in patients who received pre-transplant Mogamulizumab as compared to those who did not.<xref ref-type="bibr" rid="article-24210.r41">[41]</xref> More prospective studies are needed to evaluate the safety and efficacy of Mogamulizumab given before or after allo-HSCT.</p>
        <p>&#x000a0; &#x000a0; &#x000a0; &#x000a0;3. <bold>Alemtuzumab</bold></p>
        <p>Alemtuzumab is a humanized monoclonal antibody against CD52 that has demonstrated clinical activity against chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL), and peripheral T-cell lymphoma (PTCL). &#x000a0;ATL cells express CD52 more frequently than other peripheral T cell lymphoma. Alemtuzumab, in combination with cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen, was evaluated in 24 patients with peripheral T-cell lymphoma (PTCL) between 2003 and 2005. A total of 17 patients (71%) achieved complete remission, and the overall median duration of response was 11 months.<xref ref-type="bibr" rid="article-24210.r42">[42]</xref> However, survival rates were unsatisfactory, and the risk of CMV infection limited its effectiveness. In a phase II study of 29 patients receiving single-agent alemtuzumab, the overall objective response rate was 52%. However, the median duration of response was only 14.5 months among the 15 responders, and the median OS was reported at 5.9 months.<xref ref-type="bibr" rid="article-24210.r43">[43]</xref></p>
        <p>&#x000a0; &#x000a0; &#x000a0; &#x000a0; 4.&#x000a0;<bold>Daclizumab</bold></p>
        <p>Daclizumab is a humanized monoclonal antibody that binds to CD25 (interleukin-2 receptor alpha chain) that is over-expressed on ATL cells. Its manufacturing was stopped in 2009 due to its side effects, including hepatic toxicity. In 2016, a new form (daclizumab high-yield process) was approved by the FDA for relapsing multiple sclerosis. In phase I/II trial of daclizumab monotherapy (8 mg/kg) for 34 patients with ATL, no response was found in 18 patients with aggressive ATL.<xref ref-type="bibr" rid="article-24210.r44">[44]</xref>&#x000a0;Lower dose daclizumab (1 mg/kg) was evaluated in combination with standard CHOP chemotherapy in a phase II trial of 15 patients with ATL. The median overall survival was ten months, and CR was 33%.<xref ref-type="bibr" rid="article-24210.r45">[45]</xref>&#x000a0;At present, daclizumab is not widely used as a treatment strategy.</p>
        <p>
<bold>5. Other novel approaches</bold>
<bold>&#x000a0;</bold>
</p>
        <p>Several new treatment strategies are being studied to increase survival. A phase II study assessing the efficacy of immunomodulatory agent Lenalidomide for aggressive ATL reported encouraging results. The ORR, OS, and median PFS were 42%, 20.3 months, 3.8 months, respectively.<xref ref-type="bibr" rid="article-24210.r46">[46]</xref> Studies reported&#x000a0;high programmed cell death ligand 1 (PD-L1) expression on ATL cells. A study demonstrated poor survival rates with PD-L1 positive ATL compared to PD-L1 negative ATL. However, administering PD-1 inhibitor nivolumab to ATL patients showed rapid progression in a phase II study.<xref ref-type="bibr" rid="article-24210.r47">[47]</xref> More studies are needed to assess the role of checkpoint inhibitors. Histone deacetylase (HDAC) inhibitors, anti-Tax vaccine, denileukin diftitox (IL-2 diphtheria toxin protein) are among the other therapy options currently being investigated.</p>
      </sec>
      <sec id="article-24210.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses are other mature T-cell malignancies, including peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), mycosis fungoides and S&#x000e9;zary syndrome. In some cases, the presence of Reed Sternberg-like cells (RS) in peripheral T-cell lymphomas (PTCLs) may lead to a misdiagnosis of lymphocyte-rich classical Hodgkin lymphoma.</p>
      </sec>
      <sec id="article-24210.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Adult T cell leukemia is chemoresistant and carries a poor prognosis despite the recent progress in treatment modalities. In general, the prognosis of acute and lymphoma subtypes is poor compared with that of chronic and smoldering types. Lymphoma Study Group from 1984 to 1987 reported that median survival time was 6 months for acute type, 10 months for the lymphoma type, and 24 months for the chronic type.<xref ref-type="bibr" rid="article-24210.r11">[11]</xref>&#x000a0;In a retrospective study of 1594 ATL patients treated with intensive combination chemotherapy and allogeneic hematopoietic stem cell transplantation between 2000 and 2009, the median survival times were 8.3, 10.6, 31.5, and 55 months in patients with acute, lymphoma, chronic, and smoldering types, respectively.&#x000a0;The median survival time was reported at 5.9 months in patients who underwent allogeneic hematopoietic stem cell transplantation (7%).<xref ref-type="bibr" rid="article-24210.r34">[34]</xref>&#x000a0;</p>
        <p>The OS at 4 years for acute, lymphomatous, chronic, and smoldering subtypes were 11%, 16%, 36%, and 52%, respectively.&#x000a0;Although outcomes appear to be slightly better when comparing two studies, the long-term prognosis of ATL is still unsatisfactory.&#x000a0;Based on 854 patients with newly diagnosed ATL between 1983 and 1987, the Japan Clinical Oncology Group-Lymphoma Study Group (JCOG-LSG) identified five prognostic factors, including advanced performance status (PS), high lactic dehydrogenase (LDH), age &#x02265;40 years, &#x02265;3 involved lesions, and hypercalcemia.<xref ref-type="bibr" rid="article-24210.r48">[48]</xref> Several researchers attempted to establish a prognostic index to determine prognosis in patients with acute and lymphoma subtypes ATL. Most recently, Katsuya et al. identified five independent poor prognostic factors for acute and lymphoma subtypes in newly diagnosed patients, including Ann Arbor stage (stage III/IV, 2 points), performance status (ECOG score 2-4, 1 point), age&#x02265;70 (1 point), serum albumin &#x02264;3.5 g/dL (1 point), and sIL-2R level&#x02265;20,000 U/mL (1 point).<xref ref-type="bibr" rid="article-24210.r7">[7]</xref>&#x000a0;Median survival times were 3.6, 7.3, and 16.2 months for patients with high (5-6 points), intermediate (3-4 points), and low risk (0-2 points).&#x000a0;</p>
        <p>Other poor prognostic factors were identified in several studies for acute and lymphoma subtypes, including bone marrow involvement, skin involvement, and monocytosis.<xref ref-type="bibr" rid="article-24210.r49">[49]</xref> Eosinophilia, high LDH, high BUN, and low albumin were found to be associated with poor prognosis in the chronic subtype of ATL.<xref ref-type="bibr" rid="article-24210.r50">[50]</xref> Additional factors associated with poor prognosis include elevated serum level of interleukin-5, expression of C-C chemokine receptor 4 (CCR4), lung resistance-related protein, p53 mutation, and p16 deletion.<xref ref-type="bibr" rid="article-24210.r51">[51]</xref><xref ref-type="bibr" rid="article-24210.r52">[52]</xref>&#x000a0;Lastly, the expression of nuclear c-Rel and interferon regulatory factor-4 (IRF-4) was found to be associated with antiviral resistance and represents a poor prognosis.<xref ref-type="bibr" rid="article-24210.r52">[52]</xref></p>
      </sec>
      <sec id="article-24210.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Opportunistic infections due to severe immunosuppression are frequently reported in patients with ATL. Prophylactic trimethoprim/sulfamethoxazole should be given for pneumocystis jirovecii pneumonia. If needed, screening can be considered. Prophylaxis against herpes-zoster virus, gram-negative bacterial and fungal infection; strongyloidiasis stercoralis infection screening should also be considered in ATL patients. Tumor lysis syndrome is an oncologic emergency with high mortality risk. Vigorous intravenous hydration, rasburicase should be initiated immediately. Allopurinol administration is generally recommended 24 hours prior to starting the anti-cancer therapy.</p>
      </sec>
      <sec id="article-24210.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Adult T cell leukemia is primarily caused by HTLV-1 infection that is transmitted through breastfeeding, sexual contact, and blood transfusion. Although most of the individuals who carry HTLV-1 infection remain asymptomatic, they are at an increased lifetime risk for developing ATL. There is no uniform screening. However, patients should avoid prolonged breastfeeding (more than six months); condom use should be encouraged by physicians. Patients should be educated for the risks of intravenous drug-related infections, including HTLV-1.</p>
      </sec>
      <sec id="article-24210.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Adult T cell leukemia is uncommon and aggressive neoplasm caused by HTLV-1 infection that infects&#x000a0;10 million people in the world. Of them, 5% of infected people eventually develop symptomatic ATL. HTLV-1 is the first human retrovirus discovered and is endemic in Japan, the Caribbean region, Africa, and some parts in the Middle East, South, and Central America. HTLV-1 transmission is through breastfeeding, sexual interaction, and blood transfusion.&#x000a0;The overall prognosis is poor. Hence,&#x000a0;preventive measures&#x000a0;are of&#x000a0;utmost importance. ATL is clinically classified into four subgroups defined by the Shimoyama criteria: acute, chronic, lymphoma, and smoldering. The treatment is chosen based on clinical and patient characteristics. Currently, chemotherapy or the antiviral regimen is the first-line treatment for aggressive type (acute, lymphoma, and chronic with unfavorable features).</p>
        <p>An antiviral regimen or watchful waiting is a reasonable first-line for smoldering and favorable chronic subtypes. Different chemotherapy regimens are used in clinical practice including&#x000a0;VCAP-AMP-VECP (vincristine, cyclophosphamide, doxorubicin, prednisone-doxorubicin, ranimustine, and prednisone-vindesine, etoposide, carboplatin, prednisone), modified EPOCH (etoposide, prednisolone, vincristine, carboplatin, and doxorubicin; carboplatin is substituted for cyclophosphamide), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone), hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone). ATL patients are increased risk of opportunistic infections due to severe immunosuppression, therefore, appropriate screening, prevention, and prompt recognition are essential. These patients are&#x000a0;likely&#x000a0;encountered by primary care physicians. Early recognition and referral to a specialist are important to avoid delay in treatment.&#x000a0;Researchers are working on novel approaches and focusing on clinical trial participation. Collaborative&#x000a0;work&#x000a0;is important to find effective therapeutic strategies&#x000a0;to improve survival in ATL.</p>
      </sec>
      <sec id="article-24210.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24210&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24210">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/adult-t-cell-leukemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24210">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24210/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24210">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24210.s15">
        <title>References</title>
        <ref id="article-24210.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tobinai</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies.</article-title>
            <source>Adv Ther</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-152</page-range>
            <pub-id pub-id-type="pmid">29411267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>DU</given-names>
              </name>
              <name>
                <surname>Proietti</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Ribas</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Ara&#x000fa;jo</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Pinheiro</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Guedes</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Carneiro-Proietti</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>577</fpage>
            <page-range>577-89</page-range>
            <pub-id pub-id-type="pmid">20610824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bazarbachi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fields</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>How I treat adult T-cell leukemia/lymphoma.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>Aug</month>
            <day>18</day>
            <volume>118</volume>
            <issue>7</issue>
            <fpage>1736</fpage>
            <page-range>1736-45</page-range>
            <pub-id pub-id-type="pmid">21673346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsuoka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jeang</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy.</article-title>
            <source>Oncogene</source>
            <year>2011</year>
            <month>Mar</month>
            <day>24</day>
            <volume>30</volume>
            <issue>12</issue>
            <fpage>1379</fpage>
            <page-range>1379-89</page-range>
            <pub-id pub-id-type="pmid">21119600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>UA</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Qiao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Acuna-Villaorduna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pradhan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Adrianzen Herrera</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sica</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Shastri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mantzaris</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Derman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kornblum</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Braunschweig</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Janakiram</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States.</article-title>
            <source>Cancer</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>126</volume>
            <issue>3</issue>
            <fpage>567</fpage>
            <page-range>567-574</page-range>
            <pub-id pub-id-type="pmid">31769871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nosaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iwanaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Imaizumi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ishitsuka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishizawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Amano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uike</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Utsunomiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ohshima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tokura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tobinai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uchimaru</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsukasaki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: A nationwide survey.</article-title>
            <source>Cancer Sci</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>108</volume>
            <issue>12</issue>
            <fpage>2478</fpage>
            <page-range>2478-2486</page-range>
            <pub-id pub-id-type="pmid">28905463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katsuya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamanaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishitsuka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Utsunomiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hanada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moriuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Saburi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyahara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sueoka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Uike</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsukasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suzushima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ohno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suzumiya</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2012</year>
            <month>May</month>
            <day>10</day>
            <volume>30</volume>
            <issue>14</issue>
            <fpage>1635</fpage>
            <page-range>1635-40</page-range>
            <pub-id pub-id-type="pmid">22473153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giam</surname>
                <given-names>CZ</given-names>
              </name>
              <name>
                <surname>Semmes</surname>
                <given-names>OJ</given-names>
              </name>
            </person-group>
            <article-title>HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma-A Tale of Two Proteins: Tax and HBZ.</article-title>
            <source>Viruses</source>
            <year>2016</year>
            <month>Jun</month>
            <day>16</day>
            <volume>8</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">27322308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furuta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yasunaga</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sugata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ueno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takenouchi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fujisawa</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Higuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mahgoub</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Melamed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bangham</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Human T-cell leukemia virus type 1 infects multiple lineage hematopoietic cells in vivo.</article-title>
            <source>PLoS Pathog</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>e1006722</fpage>
            <pub-id pub-id-type="pmid">29186194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shu</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Thudi</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Dirksen</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Rosol</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Osteolytic bone resorption in adult T-cell leukemia/lymphoma.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>702</fpage>
            <page-range>702-14</page-range>
            <pub-id pub-id-type="pmid">20214446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimoyama</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).</article-title>
            <source>Br J Haematol</source>
            <year>1991</year>
            <month>Nov</month>
            <volume>79</volume>
            <issue>3</issue>
            <fpage>428</fpage>
            <page-range>428-37</page-range>
            <pub-id pub-id-type="pmid">1751370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishitsuka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma.</article-title>
            <source>Lancet Oncol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>e517</fpage>
            <page-range>e517-26</page-range>
            <pub-id pub-id-type="pmid">25281470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gessain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cassar</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological Aspects and World Distribution of HTLV-1 Infection.</article-title>
            <source>Front Microbiol</source>
            <year>2012</year>
            <volume>3</volume>
            <fpage>388</fpage>
            <pub-id pub-id-type="pmid">23162541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lairmore</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Feuer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Erbe</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Albrecht</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>D'Souza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rosol</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression.</article-title>
            <source>Am J Pathol</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>158</volume>
            <issue>6</issue>
            <fpage>2219</fpage>
            <page-range>2219-28</page-range>
            <pub-id pub-id-type="pmid">11395400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kunnathuparambil</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Payangappadom</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Yerol</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Madhavan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sreesh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Narayanan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Devdas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ramakrishanan Kattoor</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Hypercalcemic crisis due to adult T cell leukemia: a rare cause of paralytic ileus.</article-title>
            <source>Ann Gastroenterol</source>
            <year>2012</year>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>170</fpage>
            <page-range>170-172</page-range>
            <pub-id pub-id-type="pmid">24714244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Bhumbra</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Severe refractory hypercalcaemia in HTLV-1 infection.</article-title>
            <source>J R Soc Med</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>96</volume>
            <issue>3</issue>
            <fpage>126</fpage>
            <page-range>126-7</page-range>
            <pub-id pub-id-type="pmid">12612113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ogata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ogata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kohno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Uno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ohno</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ohtsuka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Saburi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kamberi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nasu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Eosinophilia associated with adult T-cell leukemia: role of interleukin 5 and granulocyte-macrophage colony-stimulating factor.</article-title>
            <source>Am J Hematol</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>242</fpage>
            <page-range>242-5</page-range>
            <pub-id pub-id-type="pmid">9798664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graham</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Burch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Adult T-cell leukemia/lymphoma.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-8</page-range>
            <pub-id pub-id-type="pmid">24982574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Human T lymphotropic virus type-I and adult T-cell leukemia in Japan.</article-title>
            <source>Int J Hematol</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>76 Suppl 2</volume>
            <fpage>240</fpage>
            <page-range>240-5</page-range>
            <pub-id pub-id-type="pmid">12430931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicot</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Current views in HTLV-I-associated adult T-cell leukemia/lymphoma.</article-title>
            <source>Am J Hematol</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>232</fpage>
            <page-range>232-9</page-range>
            <pub-id pub-id-type="pmid">15726602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sakurai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sanada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sadamori</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fukuhara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shiraishi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Chromosome abnormalities in adult T-cell leukemia/lymphoma: a karyotype review committee report.</article-title>
            <source>Cancer Res</source>
            <year>1992</year>
            <month>Mar</month>
            <day>15</day>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>1481</fpage>
            <page-range>1481-93</page-range>
            <pub-id pub-id-type="pmid">1540956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gill</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Liebman</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Bernstein-Singer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Espina</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Cabral</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.</article-title>
            <source>N Engl J Med</source>
            <year>1995</year>
            <month>Jun</month>
            <day>29</day>
            <volume>332</volume>
            <issue>26</issue>
            <fpage>1744</fpage>
            <page-range>1744-8</page-range>
            <pub-id pub-id-type="pmid">7760890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Allard</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>L&#x000e9;vy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Arnulf</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gessain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bazarbachi</surname>
                <given-names>A</given-names>
              </name>
              <collab>French ATL therapy group</collab>
            </person-group>
            <article-title>A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma.</article-title>
            <source>Hematol J</source>
            <year>2002</year>
            <volume>3</volume>
            <issue>6</issue>
            <fpage>276</fpage>
            <page-range>276-82</page-range>
            <pub-id pub-id-type="pmid">12522449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bazarbachi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Plumelle</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Carlos Ramos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tortevoye</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Otrock</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gessain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Panelatti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <month>Sep</month>
            <day>20</day>
            <volume>28</volume>
            <issue>27</issue>
            <fpage>4177</fpage>
            <page-range>4177-83</page-range>
            <pub-id pub-id-type="pmid">20585095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kchour</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tarhini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kooshyar</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>El Hajj</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wattel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mahmoudi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hatoum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rahimi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maleki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rafatpanah</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rezaee</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Yazdi</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Shirdel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Th&#x000e9;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Farid</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bazarbachi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Jun</month>
            <day>25</day>
            <volume>113</volume>
            <issue>26</issue>
            <fpage>6528</fpage>
            <page-range>6528-32</page-range>
            <pub-id pub-id-type="pmid">19411628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsukasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Utsunomiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fukushima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takatsuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Masuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagoshi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Momita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hanada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tobinai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimoyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hotta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tomonaga</surname>
                <given-names>M</given-names>
              </name>
              <collab>Japan Clinical Oncology Group Study JCOG9801</collab>
            </person-group>
            <article-title>VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.</article-title>
            <source>J Clin Oncol</source>
            <year>2007</year>
            <month>Dec</month>
            <day>01</day>
            <volume>25</volume>
            <issue>34</issue>
            <fpage>5458</fpage>
            <page-range>5458-64</page-range>
            <pub-id pub-id-type="pmid">17968021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ratner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rauch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Caruso</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Noy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barta</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Parekh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ambinder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baydoun</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma.</article-title>
            <source>Blood Cancer J</source>
            <year>2016</year>
            <month>Mar</month>
            <day>25</day>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>e408</fpage>
            <pub-id pub-id-type="pmid">27015285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alduaij</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Butera</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Treaba</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Castillo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.</article-title>
            <source>Clin Lymphoma Myeloma Leuk</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>480</fpage>
            <page-range>480-3</page-range>
            <pub-id pub-id-type="pmid">21156467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsukasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taguchi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fukushima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Moriuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kuriyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tomonaga</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature.</article-title>
            <source>Bone Marrow Transplant</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-9</page-range>
            <pub-id pub-id-type="pmid">10037056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Tosswill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of HTLV-1-associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation.</article-title>
            <source>Br J Haematol</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>94</volume>
            <issue>4</issue>
            <fpage>713</fpage>
            <page-range>713-5</page-range>
            <pub-id pub-id-type="pmid">8826899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hishizawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kanda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Utsunomiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moriuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tanosaki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kawano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Masuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagafuji</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takanashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Atsuta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kawase</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nagamura-Inoue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sakamaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Morishima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Okamura</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ichinohe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uchiyama</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Aug</month>
            <day>26</day>
            <volume>116</volume>
            <issue>8</issue>
            <fpage>1369</fpage>
            <page-range>1369-76</page-range>
            <pub-id pub-id-type="pmid">20479287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hishizawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanosaki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takatsuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Moriuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hidaka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Uike</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sakamaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Morishima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nishiyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Utsunomiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study.</article-title>
            <source>Blood</source>
            <year>2012</year>
            <month>Aug</month>
            <day>23</day>
            <volume>120</volume>
            <issue>8</issue>
            <fpage>1734</fpage>
            <page-range>1734-41</page-range>
            <pub-id pub-id-type="pmid">22689862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iqbal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reljic</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Klocksieben</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sher</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ayala</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bazarbachi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kharfan-Dabaja</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1-Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>1695</fpage>
            <page-range>1695-1700</page-range>
            <pub-id pub-id-type="pmid">31132453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katsuya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ishitsuka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Utsunomiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hanada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moriuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Saburi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyahara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sueoka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Uike</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsukasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suzushima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ohno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Amano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shimokawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suzumiya</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>K</given-names>
              </name>
              <collab>ATL-Prognostic Index Project</collab>
            </person-group>
            <article-title>Treatment and survival among 1594 patients with ATL.</article-title>
            <source>Blood</source>
            <year>2015</year>
            <month>Dec</month>
            <day>10</day>
            <volume>126</volume>
            <issue>24</issue>
            <fpage>2570</fpage>
            <page-range>2570-7</page-range>
            <pub-id pub-id-type="pmid">26361794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fanale</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Forero-Torres</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Pro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Illidge</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Huebner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Shustov</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Oct</month>
            <day>01</day>
            <volume>32</volume>
            <issue>28</issue>
            <fpage>3137</fpage>
            <page-range>3137-43</page-range>
            <pub-id pub-id-type="pmid">25135998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fanale</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Forero-Torres</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Pro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Illidge</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uttarwar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Shustov</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.</article-title>
            <source>Blood</source>
            <year>2018</year>
            <month>May</month>
            <day>10</day>
            <volume>131</volume>
            <issue>19</issue>
            <fpage>2120</fpage>
            <page-range>2120-2124</page-range>
            <pub-id pub-id-type="pmid">29507077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horwitz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Pro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Illidge</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fanale</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Morschhauser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Domingo-Domenech</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lennard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Belada</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ill&#x000e9;s</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Tobinai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsukasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Shustov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000fc;ttmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Woolery</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Manley</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tr&#x000fc;mper</surname>
                <given-names>L</given-names>
              </name>
              <collab>ECHELON-2 Study Group</collab>
            </person-group>
            <article-title>Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>Jan</month>
            <day>19</day>
            <volume>393</volume>
            <issue>10168</issue>
            <fpage>229</fpage>
            <page-range>229-240</page-range>
            <pub-id pub-id-type="pmid">30522922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Joh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uike</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Utsunomiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saburi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takemoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suzushima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tsukasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nosaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujiwara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ishitsuka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Inagaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akinaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tomonaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tobinai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.</article-title>
            <source>J Clin Oncol</source>
            <year>2012</year>
            <month>Mar</month>
            <day>10</day>
            <volume>30</volume>
            <issue>8</issue>
            <fpage>837</fpage>
            <page-range>837-42</page-range>
            <pub-id pub-id-type="pmid">22312108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takemoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suzushima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Uozumi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Uike</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Saburi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nosaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Utsunomiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tobinai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujiwara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ishitsuka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Taira</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moriuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Imada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Akinaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tomonaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.</article-title>
            <source>Br J Haematol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>169</volume>
            <issue>5</issue>
            <fpage>672</fpage>
            <page-range>672-82</page-range>
            <pub-id pub-id-type="pmid">25733162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sugio</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kawano</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Henzan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kadowaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takase</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Muta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miyawaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamauchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takashima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yoshimoto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kamezaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takenaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iwasaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ohno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Eto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kamimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Akashi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>1608</fpage>
            <page-range>1608-1614</page-range>
            <pub-id pub-id-type="pmid">27220263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Utsunomiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moriuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Uchimaru</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Otsuka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Henzan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tomoyose</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kurosawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.</article-title>
            <source>J Clin Oncol</source>
            <year>2016</year>
            <month>Oct</month>
            <day>01</day>
            <volume>34</volume>
            <issue>28</issue>
            <fpage>3426</fpage>
            <page-range>3426-33</page-range>
            <pub-id pub-id-type="pmid">27507878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallamini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zaja</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Patti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Billio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Specchia</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Secondo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rigacci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iannitto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zoli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Torchio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tarella</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.</article-title>
            <source>Blood</source>
            <year>2007</year>
            <month>Oct</month>
            <day>01</day>
            <volume>110</volume>
            <issue>7</issue>
            <fpage>2316</fpage>
            <page-range>2316-23</page-range>
            <pub-id pub-id-type="pmid">17581918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Janik</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>O'Mahony</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pittaluga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stetler-Stevenson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Raffeld</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Waldmann</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.</article-title>
            <source>Clin Cancer Res</source>
            <year>2017</year>
            <month>Jan</month>
            <day>01</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-42</page-range>
            <pub-id pub-id-type="pmid">27486175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berkowitz</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Janik</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Stetler-Stevenson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Urquhart</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Wharfe</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Figg</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Peer</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Waldmann</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.</article-title>
            <source>Clin Immunol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>155</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-87</page-range>
            <pub-id pub-id-type="pmid">25267440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ceesay</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Matutes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Fields</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cavenagh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Devereux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mufti</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Pagliuca</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).</article-title>
            <source>Leuk Res</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>36</volume>
            <issue>7</issue>
            <fpage>857</fpage>
            <page-range>857-61</page-range>
            <pub-id pub-id-type="pmid">22209076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujiwara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nosaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taira</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Imaizumi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Moriuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishizawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tobinai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsukasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoshimitsu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Otsuka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Midorikawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ohtsu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.</article-title>
            <source>J Clin Oncol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>34</issue>
            <fpage>4086</fpage>
            <page-range>4086-4093</page-range>
            <pub-id pub-id-type="pmid">27621400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rauch</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Conlon</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Janakiram</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brammer</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Zang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Miljkovic</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Sundaramoorthi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Skidmore</surname>
                <given-names>ZL</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waldmann</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Ratner</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.</article-title>
            <source>Blood</source>
            <year>2019</year>
            <month>Oct</month>
            <day>24</day>
            <volume>134</volume>
            <issue>17</issue>
            <fpage>1406</fpage>
            <page-range>1406-1414</page-range>
            <pub-id pub-id-type="pmid">31467059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <article-title>Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Lymphoma Study Group (1984-1987).</article-title>
            <source>Leuk Res</source>
            <year>1991</year>
            <volume>15</volume>
            <issue>2-3</issue>
            <fpage>81</fpage>
            <page-range>81-90</page-range>
            <pub-id pub-id-type="pmid">2016910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takasaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Iwanaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsukasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kusano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sugahara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kamihira</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tomonaga</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL).</article-title>
            <source>Leuk Res</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>751</fpage>
            <page-range>751-7</page-range>
            <pub-id pub-id-type="pmid">17188352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsukasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bazarbachi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ratner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>O'Mahony</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Janik</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bittencourt</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Utsunomiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tobinai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting.</article-title>
            <source>J Clin Oncol</source>
            <year>2009</year>
            <month>Jan</month>
            <day>20</day>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>453</fpage>
            <page-range>453-9</page-range>
            <pub-id pub-id-type="pmid">19064971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hatta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sugawara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hirakata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kamihira</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsukasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Koeffler</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Tomonaga</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia.</article-title>
            <source>J Clin Oncol</source>
            <year>1997</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>1778</fpage>
            <page-range>1778-85</page-range>
            <pub-id pub-id-type="pmid">9164185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24210.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ratner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Brites</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pedroso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Byrne</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Toomey</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Andela</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Harhaj</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Lossos</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma.</article-title>
            <source>Blood</source>
            <year>2007</year>
            <month>Apr</month>
            <day>01</day>
            <volume>109</volume>
            <issue>7</issue>
            <fpage>3060</fpage>
            <page-range>3060-8</page-range>
            <pub-id pub-id-type="pmid">17138822</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
